skip links

Media Inquiries

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]
Sort by Year
June 13, 2013

Constella® (linaclotide), the first approved prescription therapy in a new class of treatments for adults with IBS-C, is now available in Europe

June 4, 2013

Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters’ Option in Public Offering of Common Stock

May 21, 2013

Ironwood Pharmaceuticals Prices Public Offering of Common Stock

May 20, 2013

Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock

May 14, 2013

Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013

May 7, 2013

Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference

April 23, 2013

Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update

April 2, 2013

Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call

March 4, 2013

Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors

February 25, 2013

Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference

February 11, 2013

Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D

January 15, 2013

Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update

January 10, 2013

Ironwood Pharmaceuticals to Host Fourth Quarter 2012 Investor Update Call

January 4, 2013

Ironwood Completes $175 Million Debt Offering

January 2, 2013

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference